Abrupt decline in oxycodone-caused mortality after implementation of Florida's Prescription Drug Monitoring Program

Drug and Alcohol Dependence

Volumn 150, Issue , 2015, Pages 63-68

  Delcher, Chris ^a   Wagenaar, Alexander C ^a   Goldberger, Bruce A ^a   Cook, Robert L ^a   Maldonado Molina, Mildred M ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Drug related mortality; Prescription drug monitoring; Prescription pain medication; Time series

Indexed keywords

OXYCODONE; PRESCRIPTION DRUG;

ADULT; ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG FATALITY; DRUG LEGISLATION; DRUG MISUSE; DRUG MONITORING; FEMALE; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRESCRIPTION DRUG DIVERSION; PRIORITY JOURNAL; QUASI EXPERIMENTAL STUDY; TIME SERIES ANALYSIS; TREND STUDY; UNITED STATES; YOUNG ADULT; ADOLESCENT; CAUSE OF DEATH; DRUG PACKAGING; EPIDEMIOLOGY; LAW ENFORCEMENT; PAIN CLINIC; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TRENDS;

ADOLESCENT; ADULT; CAUSE OF DEATH; DRUG MONITORING; DRUG PACKAGING; FEMALE; FLORIDA; HUMANS; LAW ENFORCEMENT; MALE; MIDDLE AGED; MODELS, STATISTICAL; OXYCODONE; PAIN CLINICS; PRESCRIPTION DRUGS; YOUNG ADULT;

EID: 84926409730     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2015.02.010     Document Type: Article

References (43)

1. Alliance of States with Prescription Drug Monitoring Programs PMP Legislation & Operational Dates 2013, 〈http://www.pmpalliance.org/content/pmp-legislation-operational-dates〉 (accessed 8.26.13).
2. Alvarez L. Florida Laws Shutting Pill Mills. N.Y. Times 2011.
3. Baehren D.F., Marco C.A., Droz D.E., Sinha S., Callan E.M., Akpunonu P. A statewide prescription monitoring program affects emergency department prescribing behaviors. Ann. Emerg. Med. 2010, 56:19-23.
4. Box G., Jenkins G.M. Time Series Analysis: Forecasting & Control 1976, Prentice Hall, New Jersey, NY. second ed.
5. Butler S.F., Cassidy T.A., Chilcoat H., Black R.A., Landau C., Budman S.H., Coplan P.M. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J. Pain 2012, 14:351-358.
6. Centers for Disease Control and Prevention CDC grand rounds: prescription drug overdoses-a U.S. epidemic. Morb. Mortal. Wkly. 2012, 61:10-13.
7. Centers for Disease Control and Prevention Policy Impact: Prescription Painkiller Overdoses 2013, Centers for Disease Control and Prevention, 〈http://www.cdc.gov/HomeandRecreationalSafety/pdf/PolicyImpact-PrescriptionPainkillerOD.pdf〉.
8. Cheng J., Edwards L.J., Maldonado-Molina M.M., Komro K.A., Muller K.E. Real longitudinal data analysis for real people: building a good enough mixed model. Stat. Med. 2010, 29:504-520.
9. Cicero T.J., Ellis M.S., Surratt H.L. Effect of abuse-deterrent formulation of OxyContin. N. Engl. J. Med. 2012, 367:187-189.
10. Cook T.H., Campbell D.T. Quasi-Experimentation 1979, Houghton Mifflin, Boston, MA.
11. Coplan P.M., Kale H., Sandstrom L., Landau C., Chilcoat H.D. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiol. Drug Saf. 2013, 22:1274-1282.
12. Dart R.C., Surratt H.L., Cicero T.J., Parrino M.W., Severtson S.G., Bucher-Bartelson B., Green J.L. Trends in opioid analgesic abuse and mortality in the United States. N. Engl. J. Med. 2015, 372:241-248.
13. Dasgupta N., Creppage K., Austin A., Ringwalt C., Sanford C., Proescholdbell S.K. Observed transition from opioid analgesic deaths toward heroin. Drug Alcohol Depend. 2014, 145:238-241.
14. Davis C.S., Pierce M., Dasgupta N. Evolution and convergence of state laws governing controlled substance prescription monitoring programs, 1998-2011. Am. J. Public Health 2014, 104:1389-1395.
15. Division of Medical Quality Assurance (MQA) Services Health Care Practitioner Data Portal 2014, Division of Medical Quality Assurance (MQA) Services, 〈https://ww2.doh.state.fl.us/downloadnet/Main.aspx〉.
16. Florida Department of Health Pain Management Clinic Registration Information and Registration Relinquishment Form 2010, Florida Department of Health, 〈http://www.floridahealth.gov/licensing-and-regulation/pain-management-clinics/_documents/relinquish-clinic-registration-form.pdf〉.
17. Florida Department of Health 2013-2014 Prescription Drug Monitoring Program Annual Report (E-FORCSE) 2014, Florida Department of Health.
18. Florida House Florida House Bill 7095 2011.
19. Florida Medical Examiners Commission Drugs Identified in Deceased Persons 2013, Florida Department of Law Enforcement, Medical Examiners Commission.
20. Florida's Prescription Drug Monitoring Program E-FORCSE Prescription Drug Monitoring Program Monthly Registration & Utilization 2012, Florida's Prescription Drug Monitoring Program, 〈http://www.doh.state.fl.us/mqa/pdmp/Monthly_Registration_Utilization.html〉.
21. Goldberger B., Thogmartin J., Johnson H., Paulozzi L., Rudd R., Ibrahimova A. Drug overdose deaths-Florida, 2003-2009. Morb. Mortal. Wkly. 2011, 60:869-872.
22. Green T.C., Mann M.R., Bowman S.E., Zaller N., Soto X., Gadea J., Cordy C., Kelly P., Friedmann P.D. How does use of a prescription monitoring program change medical practice?. Pain Med. 2012, 13:1314-1323.
23. Green T.C., Zaller N., Rich J., Bowman S., Friedmann P. Revisiting Paulozzi et al.'s prescription drug monitoring programs and death rates from drug overdose. Pain Med. 2011, 12:982-985.
24. Gugelmann H.M., Perrone J. Can prescription drug monitoring programs help limit opioid abuse?. JAMA 2011, 306:2258-2259.
25. Gugelmann H., Perrone J., Nelson L. Windmills and pill mills: can PDMPs tilt the prescription drug epidemic?. J. Med. Toxicol. 2012, 8:378-386.
26. Haffajee R.L., Jena A.B., Weiner S.G. Mandatory use of prescription drug monitoring programs. JAMA 2015, 10.1001/jama.2014.18514.
27. Jann M., Kennedy W.K., Lopez G. Benzodiazepines: a major component in unintentional prescription drug overdoses with opioid analgesics. J. Pharm. Pract. 2014, 27:5-16.
28. Johnson H., Paulozzi L., Porucznik C., Mack K., Herter B. Hal Johnson Consulting and Division of Disease Control and Health Promotion. Florida Department of Health, Decline in drug overdose deaths after state policy changes-Florida, 2010-2012. MMWR Morb. Mortal. Wkly. Rep. 2014, 63:569-574.
29. Jones C.M., Mack K.A., Paulozzi L.J. Pharmaceutical overdose deaths, United States, 2010. JAMA 2013, 309:657-659.
30. KASPER Evaluation Team, Blumenschein K., Fink J., Freeman P., Kirsh K., Steinke D., Talbert J. Independent Evaluation of the Impact and Effectiveness of the Kentucky All Schedule Prescription Electronic Reporting Program (KASPER) 2010, Institute for Pharmaceutical Outcomes and Policy, Lexington, KY.
31. Lee D., Delcher C., Maldonado-Molina M.M., Bazydlo L.A.L., Thogmartin J.R., Goldberger B.A. Trends in licit and illicit drug-related deaths in Florida from 2001 to 2012. Forensic Sci. Int. 2014, 245C:178-186.
32. Levy J., Segal L., Fuchs Miller A. Prescription Drug Abuse, Strategies to Stop the Epidemic 2013, Trust for America's Health, Robert Wood Johnson Foundation, New York, NY.
33. McDowall D. Interrupted Time Series Analysis 1980, Sage, Newbury Park, CA.
34. Medical Examiner's Commission Drugs Found in Deceased Persons, Data Analysis of 2005-2008 2008, Medical Examiner's Commission, Florida.
35. Paone D. Opioid analgesics in New York City. Presented at 142nd APHA Annual Meeting and Exposition, November, 2014 2013.
36. Paone Denise, O'Brien Daniella Bradley, Tuazon Ellenie Drug use trends in New York City: 2013. Proceedings of the Community Epidemiology Work Group 2014.
37. Paulozzi L.J. Prescription drug overdoses: a review. J. Saf. Res. 2012, 43:283-289.
38. Paulozzi L.J., Kilbourne E.M., Desai H.A. Prescription drug monitoring programs and death rates from drug overdose. Pain Med. 2011, 12:747-754.
39. Rigg K.K., Kurtz S.P., Surratt H.L. Patterns of prescription medication diversion among drug dealers. Drugs Educ. Prev. Policy 2012, 19:145-155.
40. SAS Institute SAS/STAT 9.2 User's Guide 2008, SAS Institute, Inc., Cary, NC.
41. Sauber-Schatz E.K., Mack K.A., Diekman S.T., Paulozzi L.J. Associations between pain clinic density and distributions of opioid pain relievers, drug-related deaths, hospitalizations, emergency department visits, and neonatal abstinence syndrome in Florida. Drug Alcohol Depend. 2013, 33:161-166.
42. Surratt H.L., O'Grady C., Kurtz S.P., Stivers Y., Cicero T.J., Dart R.C., Chen M. Reductions in prescription opioid diversion following recent legislative interventions in Florida. Pharmacoepidemiol. Drug Saf. 2014, 23:314-320.
43. White House Epidemic: Responding to America's Prescription Drug Abuse Crisis 2011, White House, Washington, DC.